Navigation Links
UT MD Anderson scientists find protein that reins in runaway network
Date:1/22/2013

HOUSTON Marked for death with molecular tags that act like a homing signal for a cell's protein-destroying machinery, a pivotal enzyme is rescued by another molecule that sweeps the telltale targets off in the nick of time.

The enzyme, called TRAF3, lives on to control a molecular network that's implicated in a variety of immune system-related diseases if left to its own devices.

The University of Texas MD Anderson scientists identified TRAF3's savior and demonstrated how it works in a paper published online Sunday in Nature.

By discovering the role of OTUD7B as TRAF3's protector, Shao-Cong Sun, Ph.D., professor in MD Anderson's Department of Immunology, and colleagues filled an important gap in their understanding of a molecular pathway discovered in Sun's lab.

"Genetic defects or constant degradation of TRAF3 lead to the uncontrolled activity of what we call the non-canonical NF-kB pathway. This in turn, is associated with autoimmune diseases and lymphoid malignancies such as multiple myeloma and B cell lymphomas," Sun said. "Understanding how the degradation of TRAF3 is regulated is extremely important."

Dodging annihilation, turning the tables

Sun earlier found an alternative, or non-canonical, pathway that activates the protein complex known as NF-kB, a family of proteins that turns on genes that are important in immune response, inflammation, cell growth and survival, and development.

They found that NF-kB activity increases when TRAF3 has the homing targets, called ubiquitins, attached to it and is destroyed by the proteasome, a complex of proteins that hunts down ubiquitin-decorated proteins.

When TRAF3 evades attack, it turns that same destructive mechanism against NIK, a protein that's central to NF-kB activity, by tagging it with ubiquitins.

The key question was: What regulates TRAF3's destruction and, in the process, controls NF-kB?

OTUD7B emerges

Sun and colleagues had a candidate, the enzyme OTUD7B, also known by its more lyrical name, Cezanne. It was genetically quite similar to another enzyme active in the canonical pathway for NF-kB called A20. Both were known deubiquitinases, enzymes that cleave ubiquitin polymers. A20 is not active in the non-canonical NFkB pathway.

By applying inducers of the non-canonical NK-kB pathway to cells derived from OTUD7B-deficient mice, the researchers found:

  • Degradation of TRAF3 and accumulation of its target, NIK
  • Ubiquitination of TRAF3

Cells with OTUD7B intact suppressed non-canonical NF-kB signaling.

Varied immune effects in mice

Knocking out the OTUD7B gene caused biological changes in mice, but it did not kill them, as occurs when A20 is knocked out.

Mice with OTUD7B suppressed had greatly increased lymphoid cell growth in the lining of the intestine and hyper-responsiveness to antigens by B cells. "If these two symptoms occur persistently, as they did in the knockout mice, they may contribute to autoimmunity or inflammation," Sun said.

However, knockout mice also had an improved immune response to the lethal intestinal bacterial pathogen C. rodentium. All of the mice with normal OTUD7B died of the bacterial infection, while 75 percent of the knockout mice survived.

Teasing out the reasons for these effects and developing OTUD7B as a target for inhibitors to boost immunity in the lining of the intestine will take more research, Sun said.

"It's important to know that TRAF3 has opposing roles in regulating activation of T cells and B cells, indicating that OTUD7B has a cell-type specific function. So, as with many other research findings, it might take considerably more effort to assess the therapeutic potential of OTUD7B," Sun said.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. UT MD Anderson, GlaxoSmithKline to collaborate on new approach to cancer immune therapy
2. Horner Flooring to provide court for the MD Anderson Proton Therapy Showcase in Houston.
3. UT MD Anderson study finds link between statins and improved survival in inflammatory breast cancer
4. UT MD Anderson Cancer Center launches unprecedented Moon Shots Program
5. UT MD Anderson study finds link between depressive symptoms and cancer survival
6. UT MD Anderson President Ronald DePinho elected to National Academy of Sciences
7. University of Houston Graduate College of Social Work announces partnership with MD Anderson
8. UT MD Anderson study finds cancer related pain often undertreated
9. Study Finds Older Male Scientists Likelier to Commit Research Fraud
10. NIH scientists identify protective role for antibodies in Ebola vaccine study
11. Johns Hopkins neuroscientists win National Academy of Science Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... If the devil is in ... red these days. According to recent estimates, 75 – 80% of the medical ... Some studies point to Electronic Health Records (EHR) with automated features designed to ...
(Date:6/25/2017)... CA (PRWEB) , ... June 24, 2017 , ... Create a feel-good lyric music video ... above footage and sound in the timeline and write in the lyrics to any song. ... flying back out. Each line of the text can be added modularly for optimal control. ...
(Date:6/25/2017)... , ... June 25, 2017 , ... With a heatwave currently bearing down on Northern ... out at the pool. Being swimsuit ready is easy with laser hair removal. , ... again can be a burdensome routine when all you want to do is get out, ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. ... 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine ... visits to the dentist fit into their patients’ busy lifestyles. Dental365 also gladly ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation ... significant harm to people with all chronic conditions, including mental illnesses, while increasing ... place the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
(Date:6/5/2017)... -- The Cincinnati location of Diplomat ... DPLO), has been awarded a Top Workplaces 2017 ... are based on an employee survey administered by WorkplaceDynamics, LLC, ... The survey measures several aspects of workplace culture, including alignment, ... ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology: